Jim Davis

Jim Davis

As Executive Vice President, Jim is responsible for the commercialization strategy for Advera Health Analytics.

Recent Posts

October 18, 2019

Pharmacovigilance Best Practices: Establishing a Foundation of Drug Safety Success

Thanks to everyone on the great feedback we have received on this blog series focused on pharmacovigilance best practices for clinical and early post-approval biopharma companies. We've discussed discussed the importance of understanding reporting and submission to FDA, taking control of your pharmacovigilance software and creating a shared services model with your CRO.

Read More
October 11, 2019

Pharmacovigilance Best Practice #3: Use Software to Create a Shared Services Model with Your CRO

Last week's blog post discussed the importance of taking control of your pharmacovigilance software. This week we discuss Best Practice #3: Using software to create a shared services model with your CRO.

Read More
October 4, 2019

Pharmacovigilance Best Practice #2: Take Control of Your Software

Last week's blog post discussed the importance of understanding what adverse events are reportable to FDA and how they are submitted. This week we discuss Best Practice #2: Take control of your software. 

Read More
September 27, 2019

Pharmacovigilance Best Practice #1: Understand FDA adverse event reporting requirements

Last week's blog post introduced our new pharmacovigilance "best practices" series that we have put forward for clinical and early stage biopharma companies. This week we discuss Best Practice #1: Understand what is reportable and know how reports are submitted to FDA. 

Read More
September 20, 2019

Pharmacovigilance best Practices for clinical and early post-approval biopharma

The idea of selecting, implementing, and deploying pharmacovigilance software is overwhelming for smaller companies. At larger pharma companies, teams of people, vendors, and consultants are dedicated to  implement the software and keep it running. Smaller clinical and early post-approval stage biopharma companies have to make do with significantly fewer resources and they are understandably quick to look for outside help.

Read More
August 1, 2019

How to Replicate a Clinical Meta-Analysis Study in Evidex

Traditionally, safety related meta-analyses have been costly, taken significant time to produce and can often miss relevant studies. Further, there has been no efficient way to test the outcome of those studies prior to initiation. This has led to a lot of unnecessarily wasted resources. 

Luckily, Advera Health with the help of machine learning, artificial intelligence, and data science is solving this problem for drug safety, epidemiology, and medical affairs departments of all sizes. 

Last week we announced the launch of Clinical Meta-Analysis in Evidex capability and we have provided a walkthrough with screen shots is below. This new analytical tool provides the capability to perform meta-analyses of safety issues using a cloud-based software-as-a-service platform.

Read More
June 20, 2019

Busy News Week for Pharmacovigilance Software

It's been a busy week in the world of pharmacovigilance software. Major players are being acquired, new players are coming into the market, and there is more and more talk of the "next generation of PV" emerging.

First, this week it was the Wall Street Journal reporting that Nordic Capital has agreed to purchase a majority stake in ArisGlobal at a valuation of ~$700 million.  On the heels of Medidata being acquired by Dassault Systemes, the WSJ opines that both deals are bets on the "...increasing adoption of software by the broader pharmaceutical industry".

Read More
June 13, 2019

Why Has Pharmacovigilance Software Lagged Behind Other Industries?

Since Salesforce ushered in the age of software-as-a-service (SaaS) 19 years ago, the market for software has changed dramatically, as have the products that companies have brought to market. 

The SaaS model has become so commonplace that even Salesforce itself had to clarify back in 2015 that “No Software” really meant, “No legacy software, just cloud software.” SaaS and software are now synonymous, in all but a few cases. Pharmacovigilance software is one of those few cases.

Read More
May 23, 2019

When is the Right Time to implement Signal Management Software for Pharmacovigilance?

We work with biopharma companies across the size spectrum.  When small and medium sized companies with marketed products first approach us, many of them have not implemented a software solution for signal management.  Why?  Many feel their case volumes are not high enough. Others believe they don’t have the right in-house resources. Still others have “a great spreadsheet that works just fine”. All of these excuses, err, reasons boil down to one thing: FEAR.

Read More
May 16, 2019

FAERS Data Optimization & Deduplication in Evidex Gets Even Faster

We founded Advera with the goal of designing a pharmacovigilance platform that provided a modern user interface and next generation data and analytics. The FDA Adverse Event Reporting System (FAERS) was the first dataset we integrated into our Evidex platform.  In those early days, we strived to create an optimal FAERS experience, which meant finding a way to quickly ingest, standardize, and de-duplicate the very messy raw FAERS data.

Read More